NEWS & EVENTS
Company News
Press Release
For Immediate Release
January 8, 2009
Contact: Gregg DiPietro
Leerink Swann
(617) 918-4601
Gregg.DiPietro@leerink.com
Contact: Risa Burgess
Schwartz Communications
(781) 684-0770
Leerink@schwartz-pr.com
Leerink Swann Appoints William Reiland as Managing Director, Investment Banking
Boston, MA – January 8, 2009 - Healthcare investment bank Leerink Swann announced that William Reiland has joined the firm as Managing Director, Investment Banking.
Mr. Reiland will be responsible for originating, structuring, and marketing royalty monetizations, mezzanine financings, and private equity transactions.
Prior to joining Leerink Swann, Mr. Reiland served as Managing Director at Morgan Stanley. During his 15-year career at Morgan Stanley, Mr. Reiland held numerous positions in Healthcare, including investment banker, research analyst, Head of High Yield Research, and most recently as Managing Director of Morgan Stanley Principal Investments, a $3 billion internal private equity investment group.
Mr. Reiland also co-developed Morgan Stanley’s successful royalty monetization program. As a banker, Mr. Reiland has advised on approximately 70 healthcare financing transactions totaling over $25 billion in value. In addition, he has served on the Board of Directors of several services and pharmaceutical companies, including US Oncology Holdings and JHP Pharmaceuticals.
Prior to joining Morgan Stanley, Mr. Reiland worked at Bain & Company and Fidelity Management and Research. He holds a B.A from Yale and an MBA from the Amos Tuck School of Business at Dartmouth College.
"I’m delighted to welcome Bill to our Investment Banking team,” said David Ogens, Senior Managing Director and Head of Investment Banking. "Bill has a long and impressive career built around creating value for healthcare companies. His broad range of healthcare experience in research, advisory, and investing roles will further enhance Leerink Swann’s unequaled depth in healthcare and our Firm’s ability to serve as a trusted advisor to our clients.”
About Leerink Swann
Leerink Swann is a healthcare-focused investment banking firm that provides equity research, corporate finance, strategic advisory, and asset management services for institutional, life sciences, and high-net-worth clients. Every year since 2001, Institutional Investor has named Leerink Swann “Best of the Boutiques” in several healthcare categories. Through its MEDACorp division, Leerink Swann provides biomedical-consulting services to the institutional investment community. With an internal team of experts and a dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann is a member of FINRA/SIPC. For more information, visit www.leerink.com.
- END -